Amendment to the Claims

The following listing of claims will replace all prior versions and listings of claims.

Listing of Claims:

1. (Currently Amended) An isolated nucleic acid molecule comprising a first polynucleotide sequence at least 95% identical to a second polynucleotide sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:[[X]]132 as referenced in Table 1A;

(b) a polynucleotide encoding a full length polypeptide of SEQ ID NO:[[Y]]421 or a full length polypeptide encoded by the HODFN71 cDNA Clone ID in ATCC Deposit No:[[Z]]203570, corresponding to SEQ ID NO:[[Y]]421 as referenced in Table 1A;

(c) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:[[Y]]421 or a polypeptide fragment encoded by the HODFN71 cDNA Clone ID in ATCC Deposit No:[[Z]]203570 corresponding to SEQ ID NO:[[Y]]421 as referenced in Table 1A;

(d) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:[[Y]]421 or a polypeptide fragment encoded by the HODFN71 cDNA Clone ID in ATCC Deposit No:[[Z]]203570 corresponding to SEQ ID NO:[[Y]]421 as referenced in Table 1A, wherein said fragment has biological activity;

~~(e) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y as referenced in Table 1B;~~

~~(f) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y as referenced in Table 2;~~

[[(g)]](e) a polynucleotide encoding a predicted epitope of SEQ ID NO:[[Y]]421 as referenced in Table 1B; and

[[(h)]](f) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-[[(g)]](e), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. (Currently Amended) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted form of SEQ ID NO:[[Y]]421 or a secreted form of the polypeptide encoded by the HODFN71

cDNA Clone ID in ATCC Deposit No:[[Z]]203570 corresponding to SEQ ID NO:[[Y]]421, as referenced in Table 1A.

3. (Currently Amended) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:[[Y]]421 or the polypeptide encoded by the HODFN71 cDNA sequence included in ATCC Deposit No:[[Z]]203570, which is hybridizable to SEQ ID NO:[[X]]132, as referenced in Table 1A.

4. (Currently Amended) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:[[X]]132 or the HODFN71 cDNA sequence included in ATCC Deposit No:[[Z]]203570, which is hybridizable to SEQ ID NO:[[X]]132, as referenced in Table 1A.

5. (Original) The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. (Original) The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. (Original) A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. (Original) A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. (Original) A recombinant host cell produced by the method of claim 8.

10. (Original) The recombinant host cell of claim 9 comprising vector sequences.

11. (Currently Amended) A polypeptide comprising a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:

(a) a full length polypeptide of SEQ ID NO:[[Y]]421 or a full length polypeptide encoded by the HODFN71 cDNA Clone ID in ATCC Deposit No:[[Z]]203570 corresponding to SEQ ID NO:[[Y]]421 as referenced in Table 1A;

(b) a secreted form of SEQ ID NO:[[Y]]421 or a secreted form of the polypeptide encoded by the HODFN71 cDNA Clone ID in ATCC Deposit No:[[Z]]203570 corresponding to SEQ ID NO:[[Y]]421 as referenced in Table 1A;

(c) a polypeptide fragment of SEQ ID NO:[[Y]]421 or a polypeptide fragment encoded by the HODFN71 cDNA Clone ID in ATCC Deposit No:[[Z]]203570 corresponding to SEQ ID NO:[[Y]]421 as referenced in Table 1A;

(d) a polypeptide fragment of SEQ ID NO:[[Y]]421 or a polypeptide fragment encoded by the HODFN71 cDNA Clone ID in ATCC Deposit No:[[Z]]203570 corresponding to SEQ ID NO:[[Y]]421 as referenced in Table 1A, wherein said fragment has biological activity; and

~~(e) a polypeptide domain of SEQ ID NO:Y as referenced in Table 1B;~~

~~(f) a polypeptide domain of SEQ ID NO:Y as referenced in Table 2; and~~

[[(g)]](e) a predicted epitope of SEQ ID NO:[[Y]]421 as referenced in Table 1B.

12. (Original) The polypeptide of claim 11, wherein said polypeptide comprises a heterologous amino acid sequence.

13. (Original) The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

14. (Original) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

15. (Original) A recombinant host cell that expresses the isolated polypeptide of claim 11.

16. (Original) A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 15 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

17. (Original) The polypeptide produced by claim 16.

18. (Original) A method for preventing, treating, or ameliorating allergic or asthmatic disorders, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

19. (Original) A method of diagnosing allergic or asthmatic disorders in a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of claim 11; and
(b) diagnosing the allergic or asthmatic disorders based on the presence or absence of said mutation.

20. (Original) A method of diagnosing allergic or asthmatic disorders in a subject comprising:
(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
(b) diagnosing the allergic or asthmatic disorders based on the presence or amount of expression of the polypeptide.

21. (Currently Amended) A method for identifying a binding partner to the polypeptide of claim 11 comprising:
(a) contacting the polypeptide of claim [[43]]11 with a binding partner; and
(b) determining whether the binding partner effects an activity of the polypeptide.

22. (Currently Amended) The gene corresponding to the cDNA sequence of SEQ ID NO:[[X]]132.

23. (Currently Amended) A method of identifying an activity in a biological assay, wherein the method comprises:
(a) expressing SEQ ID NO:[[X]]132 in a cell;
(b) isolating the supernatant;
(c) detecting an activity in a biological assay; and
(d) identifying the protein in the supernatant having the activity.

24. (Original) The product produced by the method of claim 20.